Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Public ClinicalTrials.gov record NCT01962636. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI).
Study identification
- NCT ID
- NCT01962636
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 200 participants
Conditions and interventions
Conditions
- Acute Myeloid Leukemia (AML)
- Acute Lymphocytic Leukemia (ALL)
- Chronic Myelogenous Leukemia
- Plasma Cell Leukemia
- Myelofibrosis
- Myelodysplasia
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Marginal Zone B-Cell Lymphoma
- Follicular Lymphoma
- Lymphoplasmacytic Lymphoma
- Mantle-Cell Lymphoma
- Prolymphocytic Leukemia
- Diffuse Large B Cell Lymphoma
- Lymphoblastic Lymphoma
- Burkitt's Lymphoma
- Non-Hodgkin Lymphoma
- Multiple Myeloma
Interventions
- Fludarabine Drug
- Cyclophosphamide Drug
- Total Body Irradiation Radiation
- Cyclosporine A Drug
- Mycophenylate mofetil Drug
- Umbilical cord blood Biological
Drug · Radiation · Biological
Eligibility (public fields only)
- Age range
- Up to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2016
- Primary completion
- May 13, 2026
- Completion
- May 13, 2026
- Last update posted
- May 19, 2026
2016 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Minnesota Masonic Cancer Center | Minneapolis | Minnesota | 55455 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01962636, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 19, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01962636 live on ClinicalTrials.gov.